Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
Research output: Contribution to journal › Journal article › Research › peer-review
OBJECTIVE: The aim of this study was to record prostate-specific antigen (PSA) response and overall survival (OS) for a group of metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide following progression after abiraterone treatment in the post-chemotherapy setting.
MATERIAL AND METHODS: Twenty-four mCRPC patients with progression after abiraterone treatment following primary docetaxel therapy received enzalutamide 160 mg/day. The percentage PSA response was recorded following first line docetaxel, abiraterone and enzalutamide treatment. Fischer's exact test, Mann-Whitney U test and linear regression model were used to test for differences in PSA response.
RESULTS: All patients had a follow-up of at least 3 months. The median PSA response following 1 month of enzalutamide was -12% (range -56% to 76%), while the median best PSA response was -22% (-76% to 76%). Forty-six percent had a greater than 30% decrease in PSA. The PSA response to enzalutamide did not correlate with the number of prior cancer treatments (p = 0.57), time from diagnosis to mCRPC (p = 0.11) or prior response to docetaxel (p = 0.67). However, patients treated with second line cabazitaxel had an inferior PSA response to enzalutamide (p = 0.03), and there was a trend for the PSA response to abiraterone to correlate with the PSA response to the succeeding enzalutamide (B = 0.22, p = 0.05). The median OS was 4.8 months.
CONCLUSIONS: Previous abiraterone therapy is associated with a less marked fall in PSA following enzalutamide therapy in post-chemotherapy mCRPC patients compared with reported results in randomized trials. Larger prospective studies of sequencing are warranted.
Original language | English |
---|---|
Journal | Scandinavian Journal of Urology and Nephrology |
Volume | 48 |
Issue number | 3 |
Pages (from-to) | 268-275 |
Number of pages | 8 |
ISSN | 0036-5599 |
DOIs | |
Publication status | Published - Jun 2014 |
- Aged, Androstadienes, Antineoplastic Agents, Cohort Studies, Compassionate Use Trials, Disease-Free Survival, Humans, Kallikreins, Linear Models, Male, Middle Aged, Phenylthiohydantoin, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Taxoids, Treatment Failure, Treatment Outcome
Research areas
ID: 138772277